Multifunctional RNA Therapeutics
for Metabolic and Age‑Related Disease

Gensaic is pioneering tissue-specific in vivo delivery systems and multifunctional siRNA constructs to durably address the root causes of metabolic dysfunction and aging.

Explore Our Platform View Pipeline
0+
Therapeutic Programs
0+
Tissues Unlocked
0+
Dual Biology In Vivo PoC
200+
Sequence Space
Our Platform
The Gensaic
FORGE Engine
Step 01
Unbiased Tissue-Targeting Screen
We begin with a diverse library of candidate delivery ligands — billions of molecular variants spanning chemical space — and screen them without prior assumptions about which will home to specific tissues in vivo.
In vivo screening Unbiased library Tissue selectivity
Step 02
AI-Guided Discovery
Protein language models trained on deep sequencing datasets map sequence to function — identifying functional ligands that achieve tissue-selective enrichment from within vast, uncharted sequence space.
Protein language models Sequence-to-function AI discovery
Step 03
siRNA Payload Conjugation
Dual siRNA strands are conjugated directly to the delivery ligand, creating a programmable therapeutic capable of targeting tissues with precision in vivo — sequence-specific silencing guided by the delivery vehicle itself.
siRNA conjugation Programmable payload In vivo targeting
Step 04
Dual Biology Targeting
We leverage AI to identify gene combinations that drive the most meaningful biology — findings we validate through dual silencing in vivo, intervening at the network level for efficacy beyond single-target approaches.
Novel biology discovery In vivo validation Network intervention
Step 05
Cardiometabolic Market Opportunity
Dual-gene silencing unlocks multiple large indications across cardiometabolic disease — a >$260B total addressable market with significant unmet need in obesity, MASH, heart failure, and metabolic syndrome.
Obesity + Lean Mass MASH / MAFLD >$260B TAM
Click to explore each step
01
Unbiased Screen
02
AI-Guided Discovery
03
Payload Conjugation
04
Dual Gene Targeting
05
Cardiometabolic Market
Ionizable Lipid Nanoparticle Liver homing Hepatocyte Tissue-Selective Biodistribution Late Endosome RISC Endosomal Escape & RISC Loading target mRNA Durable mRNA Silencing 90% mRNA knockdown
Pipeline

Therapeutic Programs

Leveraging precision tissue delivery and multifunctional siRNA technologies to address chronic cardiometabolic diseases with safe, potent, and durable RNA medicines.

Program Discovery Lead Opt. IND Phase I
Obesity + Lean Mass
Adipose · Skeletal Muscle
Lead Opt.
Obesity + MASH
Adipose · Liver
Lead Opt.
Cardiometabolic Disease
Adipose
Discovery
Team

Built by Drug Developers, Scientists, and Engineers

Deep expertise spanning protein engineering, RNA therapeutics, AI/ML, and metabolic disease drug development.

Lavi Erisson
Lavi Erisson
CEO · Co-Founder · Board Member
Uyanga Tsedev
Uyanga Tsedev
CSO · Co-Founder
Jonathan Hsu
Jonathan Hsu
CTO · Co-Founder
Alex Wang
Alex Wang
Senior Scientist
Maggie Lejeune
Maggie Lejeune
Associate Scientist
Maya Orzach
Maya Orzach
Senior Research Associate
Jonathan Sands
Jonathan Sands
Senior Research Associate
Evans Wralstad
Evans Wralstad
Senior Scientist
Emanuel Burgos
Emanuel Burgos
Computational Biologist
Neo Ruiz
Neo Ruiz
Research Associate
Gabrielle Mitchell-Lee
Gabrielle Mitchell-Lee
Senior Research Associate
Sungmin Baek
Sungmin Baek
Senior Scientist
Board of Directors
Jeremy Levin
Chairman
Liang Schweizer
Board Member
Neil Exter
Board Member
Jill Milne
Board Member
Karina Thorn
Board Observer
News & Science

Latest from Gensaic

Contact

Partner With
Gensaic

We welcome collaborations with pharma, biotech, academic institutions, and investors aligned with our mission to bring durable multifunctional RNA medicines to patients with metabolic and age-related disease.

Email   info@gensaic.com
Location   LabCentral 238, Cambridge, MA